CD8A and breast carcinoma: Second, previous studies have mostly focused on how TIL-CD8+ T cells influence clinical prognosis or immunotherapy outcomes (17, 18), which is different from the present work, which started from the perspective of identifying cr-TILCD8Ts in breast cancer for chemotherapy stratification.